140 related articles for article (PubMed ID: 35545501)
1. Liver transplantation in China: Achievements over the past 30 years and prospects for the future.
Mi S; Jin Z; Qiu G; Xie Q; Hou Z; Huang J
Biosci Trends; 2022 Jul; 16(3):212-220. PubMed ID: 35545501
[TBL] [Abstract][Full Text] [Related]
2. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
4. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
6. HCC in living donor liver transplantation: can we expand the Milan criteria?
Kwon CH; Kim DJ; Han YS; Park JB; Choi GS; Kim SJ; Joh JW; Lee SK
Dig Dis; 2007; 25(4):313-9. PubMed ID: 17960066
[TBL] [Abstract][Full Text] [Related]
7. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
8. Living donor liver transplantation for hepatocellular carcinoma.
Lee SG; Moon DB
Recent Results Cancer Res; 2013; 190():165-79. PubMed ID: 22941020
[TBL] [Abstract][Full Text] [Related]
9. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
Zheng SS; Xu X; Wu J; Chen J; Wang WL; Zhang M; Liang TB; Wu LM
Transplantation; 2008 Jun; 85(12):1726-32. PubMed ID: 18580463
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
12. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
[TBL] [Abstract][Full Text] [Related]
13. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.
Al-Ameri AAM; Wei X; Lin L; Shao Z; Guo H; Xie H; Zhou L; Zheng S; Xu X
BMC Cancer; 2019 Nov; 19(1):1136. PubMed ID: 31752756
[TBL] [Abstract][Full Text] [Related]
14. Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence.
Chan SC
Transplantation; 2014 Apr; 97 Suppl 8():S7-S10. PubMed ID: 24849840
[TBL] [Abstract][Full Text] [Related]
15. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.
Al-Ameri AAM; Wei X; Liu P; Lin L; Shao Z; Xie H; Zhou L; Zheng S; Xu X
Ann Transplant; 2019 Aug; 24():489-498. PubMed ID: 31427563
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
[TBL] [Abstract][Full Text] [Related]
19. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
Xu X; Lu D; Ling Q; Wei X; Wu J; Zhou L; Yan S; Wu L; Geng L; Ke Q; Gao F; Tu Z; Wang W; Zhang M; Shen Y; Xie H; Jiang W; Wang H; Zheng S
Gut; 2016 Jun; 65(6):1035-41. PubMed ID: 25804634
[TBL] [Abstract][Full Text] [Related]
20. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
